Previous 10 | Next 10 |
An interim analysis of Aurinia Pharmaceuticals' (AUPH) LUPKYNIS (voclosporin) for lupus sustained meaningful reductions in proteinuria with no change in mean estimated glomerular filtration rate at 104 weeks of treatment.The analysis of 216 blinded subjects found that proteinuria co...
- Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment - - These data, the longest-available outcomes data with LUPKYNIS for the treatment of lupus nephritis to-date, will be presented at Europea...
Biotech stocks are officially in a slump. After a rip-roaring 2020 fueled by the advent of COVID-19 vaccines and therapeutics, the iShares Nasdaq Biotechnology ETF has now lost 10% of its value in the past three months. The industry has suddenly lost favor with investors because of ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences: RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at ...
– Company-sponsored program seeks proposals to help patients in the U.S. make informed health choices and support underserved populations with these conditions – – Submission process opens on World Lupus Day, Monday May 10, deadline to submit proposa...
The Lancet has published the results of Aurinia Pharmaceuticals' (AUPH) Phase 3 AURORA 1 study evaluating Lupkunis (voclosporin) in adults with lupus nephritis ((LN)). AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the Lupkynis...
Study results demonstrate that LUPKYNIS in combination with typical standard of care (SoC) led to statistically superior complete renal response rates compared to treatment with SoC alone Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or ...
Aurinia Pharmaceuticals ([[AUPH]] -18.2%) has plunged after the company’s Q1 financials came below expectations.Weighing on the results, Cantor Fitzgerald has maintained the overweight rating and the price target of $34.00 per share which indicates an upside of ~175.5% to the...
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...